Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2026-10-19	큐리언트 모카시클립, ESMO서 임상 1상 결과 공개…안전성·초기 항암효능 확인
2026-10-15	“샌디에이고 이어 런던까지”…큐리언트·론자, 이중 페이로드 ADC 플랫폼 글로벌 사업화 박차
2026-10-14	큐리언트-론자 이중 페이로드 플랫폼 ‘SYN-duo® CC’ 월드 ADC서 첫선
2026-10-13	큐리언트, 론자와 이중 페이로드 ADC 플랫폼 공동사업화 계약 체결
2026-10-12	Lonza Expands Dual-Payload ADC Technology Offering Through Exclusive Access to Qurient’s CDK7 Inhibitors

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More